|
1
|
World Health Organization, . Global cancer
burden growing, amidst mounting need for services. https://www.who.int/news/item/01-02-2024-global-cancer-burden-growing--amidst-mounting-need-for-servicesJune
8–2024
|
|
2
|
Wang L, Lu B, He M, Wang Y, Wang Z and Du
L: Prostate cancer incidence and mortality: Global status and
temporal trends in 89 countries from 2000 to 2019. Front Public
Health. 10:8110442022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
CDC. United States Cancer Statistics, .
Prostate Cancer Incidence by Stage at Diagnosis. https://www.cdc.gov/united-states-cancer-statistics/publications/prostate-cancer.htmlMarch
22–2025
|
|
4
|
Shore ND, Moul JW, Pienta KJ, Czernin J,
King MT and Freedland SJ: Biochemical recurrence in patients with
prostate cancer after primary definitive therapy: Treatment based
on risk stratification. Prostate Cancer Prostatic Dis. 27:192–201.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sweeney CJ, Chen YH, Carducci M, Liu G,
Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, et
al: Chemohormonal therapy in metastatic hormone-sensitive prostate
cancer. N Engl J Med. 373:737–746. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
James ND, Sydes MR, Clarke NW, Mason MD,
Dearnaley DP, Spears MR, Ritchie AW, Parker CC, Russell JM, Attard
G, et al: Addition of docetaxel, zoledronic acid, or both to
first-line long-term hormone therapy in prostate cancer (STAMPEDE):
Survival results from an adaptive, multiarm, multistage, platform
randomised controlled trial. Lancet. 387:1163–1177. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
James ND, Spears MR, Clarke NW, Dearnaley
DP, De Bono JS, Gale J, Hetherington J, Hoskin PJ, Jones RJ, Laing
R, et al: Survival with newly diagnosed metastatic prostate cancer
in the ‘docetaxel era’: Data from 917 patients in the control arm
of the STAMPEDE trial (MRC PR08, CRUK/06/019). Eur Urol.
67:1028–1038. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tannock IF, de Wit R, Berry WR, Horti J,
Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, et
al: Docetaxel plus prednisone or mitoxantrone plus prednisone for
advanced prostate cancer. N Engl J Med. 351:1502–1512. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Petrylak DP, Tangen CM, Hussain MHA, Lara
PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M,
et al: Docetaxel and estramustine compared with mitoxantrone and
prednisone for advanced refractory prostate cancer. N Engl J Med.
351:1513–1520. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mohler JL, Armstrong AJ, Bahnson RR,
D'Amico AV, Davis BJ, Eastham JA, Enke CA, Farrington TA, Higano
CS, Horwitz EM, et al: Prostate cancer, version 1.2016. J Natl
Compr Canc Netw. 14:19–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Parker C, Gillessen S, Heidenreich A and
Horwich A; ESMO Guidelines Committee, : Cancer of the prostate:
ESMO clinical practice guidelines for diagnosis, treatment and
follow-up. Ann Oncol. 26 (Suppl 5):v69–v77. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gravis G, Fizazi K, Joly F, Oudard S,
Priou F, Esterni B, Latorzeff I, Delva R, Krakowski I, Laguerre B,
et al: Androgen-deprivation therapy alone or with docetaxel in
non-castrate metastatic prostate cancer (GETUG-AFU 15): A
randomised, open-label, phase 3 trial. Lancet Oncol. 14:149–158.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
James ND, Clarke NW, Cook A, Ali A, Hoyle
AP, Attard G, Brawley CD, Chowdhury S, Cross WR, Dearnaley DP, et
al: Abiraterone acetate plus prednisolone for metastatic patients
starting hormone therapy: 5-Year follow-up results from the
STAMPEDE randomised trial (NCT00268476). Int J Cancer. 151:422–434.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hoyle AP, Ali A, James ND, Cook A, Parker
CC, de Bono JS, Attard G, Chowdhury S, Cross WR, Dearnaley DP, et
al: Abiraterone in ‘high-’ and ‘low-risk’ metastatic
hormone-sensitive prostate cancer. Eur Urol. 76:719–728. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Menges D, Yebyo HG, Sivec-Muniz S, Haile
SR, Barbier MC, Tomonaga Y, Schwenkglenks M and Puhan MA:
Treatments for metastatic hormone-sensitive prostate cancer:
Systematic review, network meta-analysis, and benefit-harm
assessment. Eur Urol Oncol. 5:605–616. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
National Comprehensive Cancer Network, .
NCCN Clinical Practice Guidelines in Oncology (NCCN
Guidelines®) Prostate Cancer, V1. 2025.https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdfMarch
23–2025
|
|
17
|
Parker C, Castro E, Fizazi K, Heidenreich
A, Ost P, Procopio G, Tombal B and Gillessen S; ESMO Guidelines
Committee, : Prostate cancer: ESMO clinical practice guidelines for
diagnosis, treatment and follow-up. Ann Oncol. 31:1119–1134. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
U.S. Department of Health and Human
Services, . Common Terminology Criteria for Adverse Events (CTCAE)
version 5.0. March 23–2025
|
|
19
|
Ferriero M, Prata F, Anceschi U, Astore S,
Bove AM, Brassetti A, Calabrò F, Chiellino S, De Nunzio C, Facchini
G, et al: Oncological outcomes of patients with high-volume mCRPC:
Results from a longitudinal real-life multicenter cohort. Cancers
(Basel). 15:48092023. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Badar F and Mahmood S: Cancer in Lahore,
Pakistan, 2010–2019: An incidence study. BMJ Open. 11:e0470492021.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Akhtar S, Hassan F, Ahmad S, El-Affendi MA
and Khan MI: The prevalence of prostate cancer in Pakistan: A
systematic review and meta-analysis. Heliyon. 9:e203502023.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhu Y, Mo M, Wei Y, Wu J, Pan J, Freedland
SJ, Zheng Y and Ye D: Epidemiology and genomics of prostate cancer
in Asian men. Nat Rev Urol. 18:282–301. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shabbir A, Khan UT, Nisar D, Rath PK,
Kumari C, Zehra T and Hasan SM: Frequency and trends of prostatic
diseases in a subset of Karachi population: A retrospective study.
Pak J Med Dent. 10:17–23. 2021.
|
|
24
|
Rush HL, Murphy L, Morgans AK, Clarke NW,
Cook AD, Attard G, Macnair A, Dearnaley DP, Parker CC, Russell JM,
et al: Quality of life in men with prostate cancer randomly
allocated to receive docetaxel or abiraterone in the STAMPEDE
trial. J Clin Oncol. 40:825–836. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chi KN, Agarwal N, Bjartell A, Chung BH,
Pereira de Santana Gomes AJ, Given R, Juárez Soto Á, Merseburger
AS, Özgüroğlu M, Uemura H, et al: Apalutamide for metastatic,
castration-sensitive prostate cancer. N Engl J Med. 381:13–24.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Davis ID, Martin AJ, Stockler MR, Begbie
S, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath
LG, et al: Enzalutamide with standard first-line therapy in
metastatic prostate cancer. N Engl J Med. 381:121–131. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vale CL, Fisher DJ, Godolphin PJ,
Rydzewska LH, Boher JM, Burdett S, Chen YH, Clarke NW, Fizazi K,
Gravis G, et al: Which patients with metastatic hormone-sensitive
prostate cancer benefit from docetaxel: A systematic review and
meta-analysis of individual participant data from randomised
trials. Lancet Oncol. 24:783–797. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fizazi K, Foulon S, Carles J, Roubaud G,
McDermott R, Fléchon A, Tombal B, Supiot S, Berthold D, Ronchin P,
et al: Abiraterone plus prednisone added to androgen deprivation
therapy and docetaxel in de novo metastatic castration-sensitive
prostate cancer (PEACE-1): A multicentre, open-label, randomised,
phase 3 study with a 2×2 factorial design. Lancet. 399:1695–1707.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Smith MR, Hussain M, Saad F, Fizazi K,
Sternberg CN, Crawford ED, Kopyltsov E, Park CH, Alekseev B,
Montesa-Pino Á, et al: Darolutamide and survival in metastatic,
hormone-sensitive prostate cancer. N Engl J Med. 386:1132–1142.
2022. View Article : Google Scholar : PubMed/NCBI
|
